Background Pulmonary hypertension (PH) is one of the most common complications of chronic obstructive pulmonary disease (COPD). PH in COPD is caused by many factors mainly hypoxia. Aim The aim was to assess prevalence and predictors of PH in COPD patients. Patients and methods A prospective, observational study was carried out on 100 patients diagnosed with COPD admitted at chest department of Alexandria university hospitals and Al. Mamoura chest hospital. All patients were subjected to complete medical history taking (Age, sex, smoking index, history of previous hospital admission for COPD exacerbation and history of previous ICU admission for the same reason), routine laboratory investigations including complete blood count (CBC), arterial blood gases (ABG), pulmonary function test (FEV1, FVC, FEV1/FVC ratio), Body mass index(BMI), six minute walk test, COPD assessment test (CAT) score, dyspnea assessment by modified Medical Research Council(m MRC) and Echocardiography relevant data (right atrial area, left atrial size, ejection fraction, valvular heart disease, PH, right ventricular function TAPSE (Tricuspid annular plane systolic excursion), systolic pulmonary artery pressure (SPAP) and tricuspid regurge velocity if present. Results A total of 100 COPD patients were included in the study 88 (88%) were males and 12 (12%) were females. Among patients with pulmonary hypertension 32 (94.1%) were males and 2 (5.9%) were females. On the other hand, 84.8%(n = 56) of patients without PH were males and 15.2%(n = 10) were females. Mean ± SD age of the patients was 60.12 ± 8.59 years. Mean ±SD age of the patients with pulmonary hypertension was 61.26±7.97 years, and for patients without PH mean± SD was 59.53 ± 8.88 years. With no statistically significant difference between the two groups. PH was diagnosed in 34 (34%) of patients, m PAP ≥25mmHg, of whom11 (32.4%) showed severe PH m PAP ≥40mmHg, 23 (67.6%) mild, moderate PH. Conclusion Although, the most important factors predicting PH in COPD patients were FEV1 and EF, respectively, but in COPD patients with severe PH was FEV1.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.